This study (2024) evaluates the diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay in detecting Alzheimer's disease pathophysiology across three observational cohorts. Results demonstrate the assay's potential to identify Alzheimer's disease biomarkers, enhancing early diagnosis and informing clinical trials. Pathophysiological implications are discussed.